Literature DB >> 22082463

Recurrence of infantile hemangiomas treated with propranolol.

Lorea Bagazgoitia1, Angela Hernández-Martín, Antonio Torrelo.   

Abstract

Propranolol has shown to be effective in the treatment of infantile hemangiomas (IH), but several cases of recurrences have been reported so far. We describe five cases of IH recurrence after propranolol treatment was stopped in 26 patients treated with propranolol all of whom were observed for at least 9 months after treatment was discontinued. Recurrence was present in 5 of 26 cases, yielding a recurrence rate of 19%. All cases were in females. Time from withdrawal to recurrence ranged from 0 to 6 months. In four of five cases, the lesion relapsed after the age of 11 months. Four of the five cases presented partial recurrences, whereas in one case, recurrence was complete. In the majority of cases, recurrence appeared in the deep component of the IH. Early treatment withdrawal or a long proliferative phase of IH are potential causes of hemangioma recurrence, although the exact mechanism remains unclear. The vascular endothelial growth factor receptor might be involved, as well as incomplete apoptosis during treatment.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082463     DOI: 10.1111/j.1525-1470.2011.01644.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  16 in total

1.  Management of periorbital hemangioma by intralesional glucocorticoids and systemic propranolol: a single-center retrospective study.

Authors:  Si-Ming Yuan; Lei Cui; Yao Guo; Chun-Yan Xue; Zhi-Jian Hong; Hui-Qing Jiang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.

Authors:  Xiaorong Ma; Tinghui Zhao; Tianxiang Ouyang; Shujia Xin; Yueting Ma; Mengling Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells.

Authors:  Lan Huang; Hironao Nakayama; Michael Klagsbrun; John B Mulliken; Joyce Bischoff
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

4.  Beta-blockers as therapy for infantile hemangiomas.

Authors:  Harrison P Nguyen; Brent B Pickrell; Teresa S Wright
Journal:  Semin Plast Surg       Date:  2014-05       Impact factor: 2.314

5.  The PHACES syndrome: Multiple episodes of reproliferation of subglottic hemangioma.

Authors:  Randall W Holdgraf; Melissa Kress
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-02-23

Review 6.  Treatment of infantile haemangiomas: recommendations of a European expert group.

Authors:  Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze
Journal:  Eur J Pediatr       Date:  2015-05-29       Impact factor: 3.183

7.  Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.

Authors:  Mohamed M D Aly; Alaa F Hamza; Hesham M Abdel Kader; Hatem A Saafan; Mohamed S Ghazy; Iman A Ragab
Journal:  Eur J Pediatr       Date:  2015-05-16       Impact factor: 3.183

Review 8.  Beta blockers: an innovation in the treatment of infantile hemangiomas.

Authors:  Shehla Admani; Stephanie Feldstein; Ernesto M Gonzalez; Sheila Fallon Friedlander
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

9.  Propranolol targets the contractility of infantile haemangioma-derived pericytes.

Authors:  D Lee; E Boscolo; J T Durham; J B Mulliken; I M Herman; J Bischoff
Journal:  Br J Dermatol       Date:  2014-08-28       Impact factor: 9.302

10.  Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas.

Authors:  Shinji Kagami; Yoshihiro Kuwano; Sayaka Shibata; Yuta Uwajima; Daisuke Yamada; Akie Miyamoto; Takuya Miyagawa; Mayuko Araki; Kohji Takahashi; Sayako Isomura; Naohiko Aozasa; Yuri Masui; Mizuho Yamamoto; Ryo Inuzuka; Tatsuo Katori; Shinichi Sato
Journal:  Eur J Pediatr       Date:  2013-06-29       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.